









市场行情
/
股票
/
nasdaq-bmrn
/

BioMarin Pharmaceutical Inc

BMRN

61.150USD

+9.200+17.71%

收盘 12/19, 16:00（美东）报价延迟15分钟

11.75B总市值

22.49市盈率 TTM



BioMarin Pharmaceutical Inc

61.150

+9.200+17.71%

概览公司财务分析

概览

公司

财务

分析

关于 BioMarin Pharmaceutical Inc 公司

BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

BioMarin Pharmaceutical Inc简介



公司代码BMRN

公司名称BioMarin Pharmaceutical Inc

上市日期Jul 23, 1999

CEOHardy (Alexander)

员工数量3040

证券类型Ordinary Share

年结日Jul 23

公司地址770 Lindaro Street

城市SAN RAFAEL

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94901

电话14155066700

网址https://www.biomarin.com/

公司代码BMRN

上市日期Jul 23, 1999

CEOHardy (Alexander)

BioMarin Pharmaceutical Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-26.15%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

Mr. Timothy Walbert

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

46.80K

-26.15%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

43.51K

-7.06%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

其他

84.92M

10.45%

地区USD

名称

营收

占比

United States

272.55M

33.53%

Europe

243.14M

29.91%

Rest of the world

142.74M

17.56%

Latin America

98.12M

12.07%

ALDURAZYME net product revenues marked by Sanofi

56.44M

6.94%

业务

地区

业务USD

名称

营收

占比

Voxzogo

221.39M

27.23%

Vimizim

215.42M

26.50%

Naglazyme

128.87M

15.85%

Palynziq

105.94M

13.03%

Aldurazyme

56.44M

6.94%

其他

84.92M

10.45%

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.63%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

其他

61.26%

持股股东

占比

The Vanguard Group, Inc.

9.63%

BlackRock Institutional Trust Company, N.A.

8.98%

PRIMECAP Management Company

7.93%

Dodge & Cox

7.64%

State Street Investment Management (US)

4.56%

其他

61.26%

股东类型

持股股东

占比

Investment Advisor

46.12%

Investment Advisor/Hedge Fund

37.47%

Hedge Fund

6.71%

Pension Fund

3.35%

Sovereign Wealth Fund

1.40%

Research Firm

1.35%

Bank and Trust

1.06%

Individual Investor

0.74%

Venture Capital

0.35%

其他

1.43%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

1296

187.90M

108.82%

+71.66K

2025Q3

1334

187.86M

111.13%

-2.15M

2025Q2

1344

190.17M

114.04%

-8.63M

2025Q1

1331

198.83M

113.78%

-19.35M

2024Q4

1317

196.49M

110.91%

+4.70M

2024Q3

1283

191.71M

111.61%

-4.43M

2024Q2

1271

195.66M

108.22%

+2.33M

2024Q1

1257

193.46M

109.63%

-14.58M

2023Q4

1275

195.75M

103.93%

+7.49M

2023Q3

1255

188.56M

102.57%

+2.75M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

18.91M

9.85%

-8.07K

-0.04%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

18.04M

9.39%

-79.52K

-0.44%

Jun 30, 2025

PRIMECAP Management Company

15.77M

8.21%

-2.00M

-11.26%

Jun 30, 2025

Dodge & Cox

15.11M

7.87%

+153.07K

+1.02%

Jun 30, 2025

State Street Investment Management (US)

8.85M

4.61%

+384.66K

+4.55%

Jun 30, 2025

Viking Global Investors LP

12.29M

6.4%

+1.49M

+13.78%

Jun 30, 2025

AQR Capital Management, LLC

5.58M

2.91%

+2.65M

+90.74%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.47M

1.81%

+43.19K

+1.26%

Jun 30, 2025

Millennium Management LLC

2.83M

1.48%

+2.16M

+319.74%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

First Trust NYSE Arca Biotechnology Index Fund

3.44%

Global X Genomics & Biotechnology ETF

2.98%

Invesco Biotechnology & Genome ETF

2.47%

First Trust Health Care Alphadex Fund

2.15%

Goldman Sachs Future Health Care Equity ETF

2.15%

State Street SPDR S&P Biotech ETF

1.93%

WealthTrust DBS Long Term Growth ETF

1.86%

Alger Russell Innovation ETF

1.84%

Virtus LifeSci Biotech Products ETF

1.5%

VanEck Biotech ETF

1.4%

First Trust NYSE Arca Biotechnology Index Fund

占比3.44%

Global X Genomics & Biotechnology ETF

占比2.98%

Invesco Biotechnology & Genome ETF

占比2.47%

First Trust Health Care Alphadex Fund

占比2.15%

Goldman Sachs Future Health Care Equity ETF

占比2.15%

State Street SPDR S&P Biotech ETF

占比1.93%

WealthTrust DBS Long Term Growth ETF

占比1.86%

Alger Russell Innovation ETF

占比1.84%

Virtus LifeSci Biotech Products ETF

占比1.5%

VanEck Biotech ETF

占比1.4%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

BioMarin Pharmaceutical Inc的前五大股东是谁？



BioMarin Pharmaceutical Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：18.91M，占总股份比例：9.85%。
BlackRock Institutional Trust Company, N.A.持有股份：18.04M，占总股份比例：9.39%。
PRIMECAP Management Company持有股份：15.77M，占总股份比例：8.21%。
Dodge & Cox持有股份：15.11M，占总股份比例：7.87%。
State Street Investment Management (US)持有股份：8.85M，占总股份比例：4.61%。